Praxis Precision Medicines Inc (PRAX) — Cash Flow-to-Debt Ratio
Praxis Precision Medicines Inc (PRAX) has a Cash Flow-to-Debt Ratio of -1.71x as of March 2026, meaning its operating cash flow of $-86.05 Million could theoretically repay -2% of its total liabilities ($50.24 Million) in one year. See Praxis Precision Medicines Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Praxis Precision Medicines Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Praxis Precision Medicines Inc across 8 annual periods. Also explore PRAX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Praxis Precision Medicines Inc (2018–2025)
Year-by-year debt coverage analysis for Praxis Precision Medicines Inc. For market capitalisation and broader financial context, see PRAX company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.17x | $-249.07 Million | $59.77 Million | ▼ -19.1% |
| 2024 | -3.50x | $-131.76 Million | $37.66 Million | ▲ +42.5% |
| 2023 | -6.08x | $-111.14 Million | $18.28 Million | ▼ -28.2% |
| 2022 | -4.74x | $-185.04 Million | $39.02 Million | ▼ -59.7% |
| 2021 | -2.97x | $-124.55 Million | $41.94 Million | ▲ +11.3% |
| 2020 | -3.35x | $-52.62 Million | $15.72 Million | ▲ +22.6% |
| 2019 | -4.32x | $-32.79 Million | $7.58 Million | ▼ -7.4% |
| 2018 | -4.03x | $-20.72 Million | $5.15 Million | — |